Anita Clayton, MD: New Drugs to Treat Sexual Dysfunction in Depression Patients

Article

Anita Clayton, MD, the David C. Wilson Professor and Chair of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, reports on some of the exciting new treatments in the pipeline for depression.

There are many different ways for sexual dysfunction to manifest itself as a side effect for patients taking antidepressants.

Anita Clayton, MD, the David C. Wilson Professor and Chair of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, explained in an interview with HCPLive® what doctors can do to limit sexual dysfunction as a side effect of antidepressants.

HCPLive: Are there any treatments in the pipeline you are particularly excited for that could help patients, while limiting some of the side effects?

Clayton: I'm very excited about new paradigms of treatment, treatments that may be

rapid-acting, and treatments that may work with a very short period of treatment and not be required to be continued over the long term.

One of those that's currently in development that I'm interested in is Sage217, which is GABAA agonist, an allosteric modulator that is in development for major depression.

HCPLive: Have SSRI’s been effective treating sexually dysfunctional depression patients?

Clayton: Depression itself causes sexual dysfunction in about 70% of individuals with depression.

It can vary what type, whether it's low desire or difficulty getting aroused or even not being able to have an orgasm or other pleasure.

So, if you treat a person with depression with an antidepressant, if their depression gets into remission then the sexual dysfunction that was associated with the depression itself may therefore very well improve.

If you have somebody who has sexual dysfunction as a symptom of their depression, you treat them with an antidepressant like an SSRI. All their other symptoms of depression get better, but not their sexual dysfunction then that may very well be a side effect.

A sexual side effect of the SSRI or antidepressant therapy and needs to be addressed a bit differently.

Related Videos
Rebecca A. Andrews, MD: Issues and Steps to Improve MDD Performance Measures
A Voice Detecting Depression? Lindsey Venesky, PhD, Discusses New Data
Daniel Karlin, MD: FDA Grants Breakthrough Designation to MM120 for Anxiety
Leesha Ellis-Cox: Steps to Closing the Bipolar Disorder Diagnosis Gap for Blacks
Daniel Greer, PharmD: Reduction in Rehospitalizations with Antipsychotic Injections for Schizophrenia
Understanding the Link Between Substance Use and Psychiatric Symptoms, with Randi Schuster, PhD
© 2024 MJH Life Sciences

All rights reserved.